Generic Zosyn Availability

Zosyn is a brand name of piperacillin/tazobactam, approved by the FDA in the following formulation(s):

ZOSYN (piperacillin sodium; tazobactam sodium - injectable;injection)

  • Manufacturer: WYETH PHARMS INC
    Approval date: October 22, 1993
    Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [RLD] [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [RLD] [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [RLD] [AP], EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL [RLD] [AP]

Has a generic version of Zosyn been approved?

A generic version of Zosyn has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zosyn and have been approved by the FDA:

PIPERACILLIN AND TAZOBACTAM (piperacillin sodium; tazobactam sodium injectable;injection)

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: May 23, 2011
    Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [AP]
  • Manufacturer: HOSPIRA INC
    Approval date: September 15, 2009
    Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [AP], EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL [AP]
  • Manufacturer: ISTITUTO BIO ITA SPA
    Approval date: May 31, 2011
    Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [AP], EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL [AP]
  • Manufacturer: SANDOZ
    Approval date: October 21, 2010
    Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [AP], EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zosyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compositions containing pipercillin and tazobactam useful for injection
    Patent 6,900,184
    Issued: May 31, 2005
    Inventor(s): Cohen; Jonathan Marc & Shah; Syed M. & Ofslager; Christian Luther & Fawzi; Mahdi
    Assignee(s): Wyeth Holdings Corporation
    The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
    Patent expiration dates:
    • April 14, 2023
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug product
  • Compositions containing piperacillin and tazobactam useful for injection
    Patent 7,915,229
    Issued: March 29, 2011
    Inventor(s): Cohen; Jonathan Marc & Shah; Syed Muzafar & Ofslager; Christian Luther & Fawzi; Mahdi Bakir
    Assignee(s): Wyeth Holdings Corporation
    An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
    Patent expiration dates:
    • April 14, 2023
      ✓ 
      Drug product
  • Compositions containing piperacillin and tazobactam useful for injection
    Patent 8,133,883
    Issued: March 13, 2012
    Inventor(s): Cohen; Jonathan M. & Shah; Syed M & Ofslager; Christian L. & Fawzi; Mahdi B.
    Assignee(s): Pfizer Inc.
    An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
    Patent expiration dates:
    • April 14, 2023
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide
(web2)